reSee.it - Related Video Feed

The speaker presents an illustration of clots removed from a 30-year-old man, noting the largest clot came from the femoral artery while two of the smaller clots came from the radial arteries. The footage is described as zoomed in so viewers can see that these clots are not natural and have come from inside the arteries. The speaker emphasizes that these clots are not a normal finding inside a young man of 30 years old, repeatedly asserting that “these are not natural” and “these shouldn’t be inside this young man of 30 years old.” The presenter then remarks that the case is “imprisoned and deceased in The UK,” linking the observation to events or revelations associated with Richard Hirschman. The speaker indicates an attempt to examine the clots more closely, explaining the lack of equipment (no microscope) but insisting on the visible reality of clots sitting inside the arteries, and rhetorically questions whether this is normal. The final claim made is that the individual from whom the clots were removed was a jab recipient, tying the medical observation to vaccination. Throughout, the speaker frames the findings as alarming and abnormal, stressing the combination of young age, arterial clots, and a vaccination context, while invoking Hirschman’s revelations and noting the location as The United Kingdom.

Dr. Pretorius and a colleague discuss unusual clotting observed after COVID-19 vaccination, including embalmers reporting back pressure when introducing embalming fluid and the extraction of very long, congealed clots—six inches to several feet—as well as patients with long brachial clots. They note thousands of clotting reports in VAERS across all vaccine types, describing these clots as not normal. Some clots cause major emboli affecting circulation to the lungs, detected by scans and perfusion studies, while others are microclots with a branching pattern visible in imaging. A clinician also shared a photo of a clot with a complete branching pattern into medium and smaller vessels. Dr. Pretorius’ work is cited to explain the mechanism: spike protein can induce immediate clumping of proteins in platelet-poor plasma in the absence of platelets, a highly unusual clotting pathway not relying on the classical coagulation cascade. This is described as a proteinaceous, pseudo-amyloid–like clot. The spike protein is reported to circulate after vaccination, with studies in the Journal of Immunology showing spikes in circulation and exosomes up to four months after shots. Long-haul COVID data (Patterson’s study) reportedly shows S1 protein present in nonclassical monocytes in blood, suggesting persistence of spike protein, whether from infection or the vaccine, which can induce clotting pathways on its own. Dr. Pretorius discusses observations of upregulation of intercellular adhesion molecules (ICAMs) on leukocytes within clots, causing white blood cells to adhere in addition to fibrin, contributing to difficulty in dissolving these clots. Concerning treatment and detection, the speakers describe depletion of plasminogen, reducing the body’s ability to break down clots, and note that standard anticoagulants are less effective against these clots, which are described as amyloid-like and atypical. They emphasize that these are not the classical clotting pathways involving platelet activation and typical thrombin–fibrin cascades. They contrast this with expectations of standard clotting mechanisms and reference the unusual, non-classical pathway highlighted by Pretorius. The discussion also mentions the idea that spike protein in circulation can drive clotting without the usual platelet activation, and that some patients have continued to experience spike-related effects long after vaccination. They assert that vaccines were developed targeting the original Wuhan strain and may not cover Omicron; they suggest the shot’s risk-benefit balance is unfavorable given ongoing clotting, immune suppression, and cancer-inducing pathways, and they claim data indicate those who receive two or three shots may acquire Omicron at a higher rate than those unvaccinated. They conclude that the shot is expired for a virus that is no longer circulating in its original form and argue that vaccination induces dangerous pathologic processes with no protective benefit.

The CDC in the US has found numerous issues related to vaccines. There are high rates of miscarriage, severe prematurity, and birth defects in children. The CDC comments on gynecological side effects, specifically blood clots in the placenta. Babies are being born with clots in their placenta, which may be linked to the vaccine's effects. Placenta analysis often reveals thrombosis, and healthcare professionals have reported finding small clots regularly. Further studies and analysis are needed to fully understand this issue.

I got the vaccine. Did you really? Yeah, even the fourth one. Were you pressured into it? Kind of. I went to the doctor for blood work, and we noticed some unusual particles. I asked what they were, and the doctor revealed they were related to the vaccine. I was shocked. This is why some people experience severe issues, like having numerous white blood clots in their blood.

Genes from injected vaccines enter bloodstream and cells lining vessel walls, producing spikes. Lymphocytes attack these cells, leading to clot formation. Antibodies appear after 3-4 weeks, attacking vessel wall cells. Vaccination creates unique situation with unknown outcome. Advises against second or any future shots due to potential dangers revealed in recent publications. Calls for discussion and action to address potential risks.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

There have been reports of blood clots in patients who have received the vaccine. These clots have been found in living patients and have also been observed in post-mortem examinations. The clots are made up of fibrous material and unusual combinations of proteins that make them difficult for the body to dissolve. However, it is important to note that not everyone who receives the vaccine will experience these clots. One possible solution is the use of an enzyme called Nattokinase, derived from fermented soy, which has been shown to break down fibrin and dissolve clots. Further research is needed to fully understand and address this issue.

Vaccines are crucial for saving lives, including those for smallpox and measles. However, the COVID vaccine has presented some challenges. Patients who received the vaccine and later contracted COVID experienced more cardiovascular complications. Additionally, booster shots caused severe vasculitic reactions, and it is unclear whether this is due to the vaccine being injected directly into the vein or if it is a result of the patient's antibodies reacting to the booster. Investigations are ongoing, and it is important to provide patients with informed choices regarding this situation. We are in need of further research and guidance to address these concerns.

A UK doctor and a US cardiologist have whistleblowers revealing an increase in white fibrous clots being removed from patients. Traditional clot-busting drugs are ineffective against these clots, requiring manual extraction in cath labs. The whistleblowers link the presence of these clots to COVID vaccine recipients, with 99% of patients having received 1 to 8 doses. The issue worsens with more vaccine doses. The whistleblowers fear repercussions for speaking out.

The data indicates that vaccinations have led to serious health issues, including blood clots, strokes, and amputations. A simple d-dimer test can reveal the presence of blood clots, yet the government has not mandated this test for vaccinated individuals. Studies by two cardiologists found that over 80% of vaccinated patients had elevated d-dimer levels, suggesting microemboli, which can cause gradual organ failure and increase the risk of severe thrombosis, particularly in the brain. Cases of thrombosis in young people are rising, likely due to microemboli and the spike protein from the vaccine affecting blood vessel walls. This connection has been established through clinical observations.

In this video, Richard Hirschman, an embalmer, discusses the abnormal blood clotting issues he has observed in bodies since early 2021. He shares that these clots are different from typical blood clots, as they are white, fibrous, and rubbery in texture. Hirschman believes that these clots may be caused by aberrant proteins resulting from the COVID vaccines. He emphasizes the need for further research and understanding of these clots and their potential impact on health. Another guest, Jamie, a funeral service professional, supports Hirschman's observations and urges people to critically evaluate the situation. The video also includes a discussion on the suppression of information and the need for scientific investigation.

A data analyst and former Air Force Major conducted a survey among embalmers nationwide. 72% reported seeing white fibrous blood clots in corpses in 2023. The analyst, Tom Haviland, conducted the survey after hearing reports of these clots. He sent out surveys to over 3 dozen funeral associations and 1700 funeral homes worldwide. The survey found that 7 out of 10 embalmers observed the clots, with most seeing them after the vaccine rollout in 2021. A follow-up survey is currently underway to gather more data for 2023.

There are real cases of blood clots in patients who have received the vaccine. These clots are thick and fibrous and can be seen in living patients. A tube of blood from a patient with cold-induced finger pain showed the same fibrils as the clots. The body has difficulty breaking down the material in the clots, including amyloid. Autopsies were discouraged early on, so these clots may not have been discovered. Morticians have noticed unusual back pressure when preserving bodies. The clots contain collected proteins and unusual combinations that are hard to dissolve. Nattokinase, an enzyme found in fermented soy, can break down fibrin and may be helpful in dissolving clots.

The speaker observed vasculitis, or inflammation of the blood vessels, in the brain tissue of almost all cases examined post-vaccination. Lymphocytes aggregate around small vessels, indicating inflammation possibly triggered by an antigenic structure like spike protein. This was described as one of the most alarming findings. Individuals with this complication may experience transient defects like loss of speech, unconsciousness, or blindness, but the brain can compensate if there is no major inflammation or hemorrhage. The speaker clarified that the individuals did not die from the vasculitis itself. It's possible for vaccinated individuals to experience these symptoms without knowing the underlying cause. Changes in character have been reported in some vaccinated individuals, which may be related to this inflammation.

The spike protein, according to research in South Africa, induces fibrin from fibrinogen, forming the backbone of clotting in a way not previously seen. Unlike normal fibrin clots that are easily broken down, clots formed from COVID or the spike protein from the vaccine are difficult to break down, causing issues for many people. A cardiologist stated that in their decades of practice, they have never treated as many blood clots as in the last five years. These blood clots occur after the virus infection and the vaccine because the spike protein causes blood clots. Therefore, it is reckless to continue vaccinating people and loading the body with spike protein, causing more blood clots. According to a paper in Cell (July 2021), the nucleoprotein, not the spike protein, supplied broad and durable immunity for the prevention of infection. The speaker questions why the vaccine wasn't changed to target the nucleoprotein once this information came to light.

I recently conducted a survey of embalmers, and 73% of the 269 respondents reported finding white fibrous clots in corpses during 2023. These clots, which consist of fibrin, platelets, and amyloid-like material, are suspected to be a contributing factor in strokes and heart attacks. Embalmers are finding these clots are making it necessary to use multiple injection sites, lengthening the embalming process. While similar clots were observed in 2020, during the initial COVID outbreak, their prevalence exploded with the introduction of vaccines in 2021. The spike protein from the virus and vaccines may be responsible for the formation of these clots. Additionally, embalmers are reporting increases in microclotting and traditional grape jelly clots. One theory suggests "frame shifting," where ribosomes misread the modified RNA code from vaccines, creating aberrant proteins that form amyloid material. I can be contacted at thomashaveland@sbcglobal.net.

In spring 2021, our ER was busier than ever due to a sudden surge in patients falling ill after COVID vaccines were introduced. We observed a significant rise in stroke cases, blood clots, heart issues, and paralysis. This shift in patient conditions highlights the impact of the pandemic on healthcare systems and the need to understand the full scope of what medical professionals have been facing.

I found many clinicians dismissing the importance of asking about vaccination status when treating patients with blood clots. Despite frustrations, I continue to see cases where this information is overlooked. Collaborating with physicians in Birmingham, we witnessed an increase in severe cases, including young individuals with atrial fibrillation. I made the decision to prioritize patient care over job security, treating over 2,000 patients, including those with vaccine injuries.

I have personally witnessed numerous side effects in my patients, including brain thrombosis, large tumors under the arm, prolonged fever, sciatica, swelling, back pain, cold edema, throat redness, shortness of breath, pericarditis, shingles, aortic thrombosis, myocarditis, migraines, chronic colds, sinusitis, cancer recurrences, cancer pain, arm paralysis, facial hemiplegia, bruising on the arm, spontaneous foot hematoma, phlebitis, lung edema, and worsened respiratory diseases. There have also been cases of coma and amputation in young individuals, as well as multiple cardiac arrests. It is concerning that many of these individuals had received the vaccine.

They said stroke only happened to the old, but hospitals started seeing something new. Healthy people suddenly clotting. Coincidence? Maybe. But after 2021, studies began tracing small patterns, inflammation, platelets, micro clots weeks after certain shots. Most never notice but for a few, the immune system hits too hard. The same spike that's meant to protect starts sticking to vessel walls. Breath thickens, flow slows, boom. Ischemia. Doctors call vaccine induced immune thrombotic events. Rare, yes, imagined, no. Its indolentacid and negem. The question isn't if it happens but why somebody's break the code. Genetics, guts, toxins, maybe all three. Because when the system builds to defend starts to misfire the result isn't protection, it's a stroke.

Residual effects from one or two COVID shots can include late blood clots and cardiac arrests years later. The mRNA and spike protein from the shots can linger in the body, causing various health issues like heart and brain damage, blood clots, and immunologic problems. A spike detox program is recommended to address these concerns.

In this video, Cody shares his experience of having a pulmonary embolism after receiving the COVID-19 mRNA vaccine in 2021. It is now 2023, and he is back in the hospital. He has a blood clot in his leg, and the doctors are checking if he has another embolism in his lungs. Cody mentions that these health issues occurred after getting the vaccine.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

Following the COVID-19 vaccine rollout, some embalmers reported finding unusual, large, dense clots in corpses' vascular systems. Thomas Haviland conducted a worldwide survey in 2023-2024, finding that these white fibrous clots were unseen pre-COVID jab, but over 70% of embalmers were seeing them in 20% of corpses post-jab. Around 20% of embalmers reported a 25% increase in infant deaths after the COVID jab. At the Tennessee Funeral Directors Association convention, Haviland found genuine interest in the clots, with most attendees indicating they had seen them. These clots are described as rubbery, hard to break, and different from typical clots. A survey in Tennessee found 70% of embalmers still seeing these clots in one out of six corpses, and 39% reported a 14% increase in infant deaths compared to pre-COVID jab years.

The speaker claims injections result in blood clots, stroke, heart attack, and lost limbs, and questions why the government hasn't ordered D-dimer tests for vaccinated individuals to assess blood clot risk. Two cardiology studies allegedly found over 80% of vaccinated patients had high D-dimer levels, indicating microemboli. Microemboli in the brain, heart, or kidneys can cause organ failure and increase susceptibility to disease, potentially leading to strokes. The speaker reports seeing more cases of thrombosis of the superior sagittal sinus and transverse sinus in the brain, particularly in young people. They attribute this to microemboli and embolism caused by the spike protein from the vaccine and a nanolipid carrier entering the blood vessel wall, which they claim has been proven.